ArticleResults in immunology2012
IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with other auto-antibodies against modified LDL.
Article in Results in immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 48 citations in OpenAlex.
- Different subclasses and isotypes of antibodies against phosphorylcholine in haemodialysis patients: association with mortality.Clinical and experimental immunology · 2020Trial
- Oral microbiome diversity associates with carotid intima media thickness in middle-aged male subjects.Communications medicine · 2025Article
- Plasma levels of anti phosphocholine IgM antibodies are negatively correlated with bone mineral density in humans.Scientific reports · 2025Article
- The immunology of B-1 cells: from development to aging.Immunity & ageing : I & A · 2024Review
- T-Cell/B-Cell Interactions in Atherosclerosis.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Supramolecular Peptide Self-Assemblies Facilitate Oral Immunization.ACS biomaterials science & engineering · 2024Article
- Engaging natural antibody responses for the treatment of inflammatory bowel disease via phosphorylcholine-presenting nanofibres.Nature biomedical engineering · 2024Article
- Dandelion Polysaccharides Ameliorate High-Fat-Diet-Induced Atherosclerosis in Mice through Antioxidant and Anti-Inflammatory Capabilities.Nutrients · 2023Article
- Systemic lupus erythematosus and cardiovascular disease.Journal of internal medicine · 2023Review
- Antibodies Against Phosphorylcholine Among 60-Year-Olds: Clinical Role and Simulated Interactions.Frontiers in cardiovascular medicine · 2022Article
- Antibodies against phosphorylcholine in hospitalized versus non-hospitalized obese subjects.Scientific reports · 2021Observational
- Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events.Arthritis research & therapy · 2021Article
- Identification of IgG1 isotype phosphorylcholine antibodies for the treatment of inflammatory cardiovascular diseases.Journal of internal medicine · 2021Article
- Potential natural immunization against atherosclerosis in hibernating bears.Scientific reports · 2021Article
- Immunoglobulin G1 Antibodies Against Phosphorylcholine Are Associated With Protection in Systemic Lupus Erythematosus and Atherosclerosis: Potential Underlying Mechanisms.ACR open rheumatology · 2020Article
- Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates VascularJACC. Basic to translational science · 2020Article
- Article
- CD6 expression has no effect on atherosclerosis in apolipoprotein E-deficient mice.BMC research notes · 2018Article
- Autoimmunity: Do IgM antibodies protect against atherosclerosis in SLE?Nature reviews. Rheumatology · 2016Article
- Natural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune disease.Journal of clinical immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe have reported that anti-phosphorylcholine (anti-PC) IgM is a protection marker for human cardiovascular disease (CVD) and atherosclerosis. We here investigate the anti-PC autoantibodies in a well-defined cohort with regard to idiotype, atherosclerosis progression and mechanisms for its protective action.
methodsSerum levels and binding specificities of different anti-PC isotypes were determined in 226 hypertensive individuals enrolled in European Lacidipine Study on Atherosclerosis using ELISA. The mean of the maximum Intima-Media Thicknesses (IMT) in the far walls of common carotids and bifurcations was assessed at the time of inclusion, and four years afterwards. Apoptosis in immune cells was induced with lysophosphatidylcholine (LPC) and quantified using the MTT-assay.
resultsAnti-PC IgM, IgA and IgG1 (but not IgG2) was negatively associated with IMT-progression. Combining anti-PC IgM with data on antibodies against oxidized- and malondialdehyde-modified LDL further strengthened this association. At very high levels, anti-PC IgM exhibited a striking negative association with atherosclerosis progression (OR 0.05; CI 0.006-0.40). Analysis of serum samples taken four years apart in study participants affirmed the stability of anti-PC IgM titers over time. Examination of fine specificities revealed that the protective isotypes (IgM, IgA and IgG1) are of the Group I idiotype whereas the non-protective IgG2 subclass was Group II. Anti-PC IgM inhibited LPC-induced cell death of immune cells.
conclusionGroup I anti-PC antibodies, particularly of the IgM class, are independent protection markers for atherosclerosis progression. One potential mechanism of action is inhibition of LPC-induced cell cytotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.